Developer of a cloud-based platform designed to provide effective therapies to patients.
Developer of a cloud-based platform designed to provide effective therapies to patients.
Other Healthcare Technology Systems📍 Palo Alto, CAFounded 2012
Current Valuation
$2.1B
as of 2021-Q4
UNICORN
QL Price
$733.04M
-65% vs last round
QuantLogix's current estimate for Medable, published 2026-09-07 — below the last disclosed round of $2.1B (2021-Q4).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$2.1B
2021-Q4
weight 0.04
Secondary market print
$651M
2026-06-27
weight 0.65
How this price has held up
No round has priced for Medable since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-07 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Medable, 2026-09-07 (4f9fafc6f3953cb4).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Medable going public?
No. Medable is private and has not filed to go public. There is no S-1 on file.
What is Medable's valuation in 2026?
Medable is valued at $2.1B as of 2021-Q4, set by its Series D ($304M, Oct 2021). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Medable filed an S-1?
No public S-1 is on file for Medable.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2012
HQ
Palo Alto, CA
Employees
650
Total Raised
$499.71M
Last Round
Series D — $304M (Oct 2021)
IPO Status
private
Fundraising Status
Series D · $304M · 4y 11mo ago
privateTotal raised $499.71M
Secondary Market
Implied price / share
$3
Last round price / share
$9.67
vs last round
-69.0%
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series D
$304M
Oct 2021
—
$2.1B
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
1
0 active · 0 recruiting
Focus areas
Coronavirus
COVID · COVID-19
Latest trial start
2020-04-20
Name-verified against lead sponsor "Medable Inc." on ClinicalTrials.gov as of 2026-09-03. Verify on ClinicalTrials.gov ↗
Talent Signal
Hiring trend
● First snapshot
trend accrues with monthly sweeps
Open roles
6
via workday
Product-build share
50%
engineering, research, product, design
Trajectory
steady
product-led hiring — 50% of open roles build product; the rest are go-to-market and G&A.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Cloud Security Operations Engineer (GCP/AWS) - RemoteSDE III, Data EngineeringDeveloper, Front EndData ManagerDirector, Digital Enablement & SolutionsProject Manager
Counted from Medable's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Health CarePharmaceuticalMessagingMedical Device
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q4. Refreshed quarterly.